CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Nivolumab-Ipilimumab

Last Updated: December 18, 2020
Result type: Reports
Project Number: PC0229-000
Product Line: Reimbursement Review

Generic Name: nivolumab-ipilimumab

Brand Name: Opdivo-Yervoy

Manufacturer: Bristol-Myers Squibb

Therapeutic Area: Malignant Pleural Mesothelioma (MPM)

Indications: ​OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

Manufacturer Requested Reimbursement Criteria1: OPDIVO, in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open September 30, 2020
Call for patient/clinician input closed November 19, 2020
Clarification:

- Patient input submission received from Lung Cancer Canada

Submission received October 29, 2020
Submission accepted November 12, 2020
Review initiated November 13, 2020
Draft CADTH review report(s) provided to sponsor for comment February 25, 2021
Deadline for sponsors comments March 08, 2021
CADTH responses on draft review report(s) provided to sponsor April 05, 2021
Expert committee meeting (initial) April 15, 2021
Draft recommendation issued to sponsor April 27, 2021
To
April 29, 2021